Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2009

View Archived Issues

Ginseng extract CVT-E002 shows promise in mouse model of asthma

Dexmedetomidine shows favorable pharmacokinetics for long-term sedation in renal failure patients

Recent Roche patent describes new benzimidazole derivatives for lipoprotein disorders

Botulinum toxin effective without anticholinergics in neurogenic detrusor hyperactivity

Novel histone deacetylase inhibitors presented by Karus Therapeutics

AstraZeneca discloses new series of Janus kinase inhibitors for cancer treatment

Dopamine D3 receptor antagonists may have potential for treating premature ejaculation

Ligand and GlaxoSmithKline collaboration identifies new lead compound

Merck KGaA and Yissum sign agreement to develop semiconductor nanoparticles

Roche claims pyridoneamide derivatives as focal adhesion kinase inhibitors

Halozyme commences PEGPH-20 dosing in patients with refractory solid tumors

Wyeth submits BLA to FDA for its 13-valent pneumococcal vaccine

FDA Advisory Committee recommends accelerated approval for Avastin

GSK's Synflorix pneumococcal vaccine receives European authorization

PF-04217903 pharmacokinetics investigated in phase I study

Phase I data on AVE-8062 in advanced solid tumor patients presented

Tadalafil lowers the ApoB/ApoA-1 ratio in healthy men

Pharming to submit MAA to EMEA for Rhucin in HAE in September 2009

GSK submits final data to FDA from phase III HPV-008 clinical study of Cervarix

QuatRx completes enrollment in second phase III clinical trial of Ophena for vaginal atrophy

NeuroSearch presents update on clinical development programs

Celtic reports positive results from phase II trial of TDT-067 for onychomycosis

GSK submits lapatinib for first-line breast cancer treatment in U.S. and E.U.

DiaMedica reports top-line results from phase IIa DM-99 study in type 2 diabetes

Once-weekly exenatide offers superior glucose control to sitagliptin or pioglitazone

KAI initiates second phase II trial for KAI-1678 in neuropathic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...